^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SY-4798

    i
    Associations
    News

    Trials

    Company:
    Shouyao Holdings
    Drug class:
    FGFR4 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor (NCT05498519)
    Phase 1
    Shouyao Holdings (Beijing) Co. LTD
    Recruiting
    Last update posted :
    05/11/2023
    Initiation :
    04/15/2021
    Primary completion :
    04/15/2024
    Completion :
    04/15/2024
    FGF19
    |
    SY-4798